Cargando…

(18)F-FLT PET/CT as a Prognostic Imaging Biomarker of Disease-Specific Survival in Patients with Primary Soft-Tissue Sarcoma

The purpose of this study was to evaluate (18)F-FLT PET/CT as an early prognostic imaging biomarker of long-term overall survival and disease-specific survival (DSS) in soft-tissue sarcoma (STS) patients treated with neoadjuvant therapy (NAT) and surgical resection. Methods: This was a 10-y follow-u...

Descripción completa

Detalles Bibliográficos
Autores principales:	Crompton, Joseph G., Armstrong, Wesley R., Eckardt, Mark A., Seyedroudbari, Ameen, Tap, William D., Dry, Sarah M., Abt, Evan R., Calais, Jeremie, Herrmann, Ken, Czernin, Johannes, Eilber, Fritz C., Benz, Matthias R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Society of Nuclear Medicine 2022
Materias:	Clinical Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9051595/ https://www.ncbi.nlm.nih.gov/pubmed/34593596 http://dx.doi.org/10.2967/jnumed.121.262502

Ejemplares similares

FDG-PET/CT Imaging Predicts Histopathologic Treatment Responses after Neoadjuvant Therapy in Adult Primary Bone Sarcomas
por: Benz, Matthias R., et al.
Publicado: (2010)

Fibroblast Activation Protein Expression in Sarcomas
por: Crane, Jacquelyn N., et al.
Publicado: (2023)

[(18)F]FDG PET/CT for evaluating early response to neoadjuvant chemotherapy in pediatric patients with sarcoma: a prospective single-center trial
por: Polverari, Giulia, et al.
Publicado: (2020)

Novel Framework for Treatment Response Evaluation Using PSMA PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer (RECIP 1.0): An International Multicenter Study
por: Gafita, Andrei, et al.
Publicado: (2022)

Developing a Patient-Reported Outcome Measure for Radionuclide Therapy for Prostate Cancer
por: Gudenkauf, Lisa M., et al.
Publicado: (2023)

Chemotherapy and Survival in Patients with Primary High-Grade Extremity and Trunk Soft Tissue Sarcoma
por: Graham, Danielle S., et al.
Publicado: (2020)

Correction to: Randomized prospective phase III trial of 68Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT]
por: Calais, Jeremie, et al.
Publicado: (2019)

Randomized prospective phase III trial of (68)Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT]
por: Calais, Jeremie, et al.
Publicado: (2019)

Soft Tissue Sarcomas of the Kidney
por: Köhle, Olivia, et al.
Publicado: (2015)

PSMA PET Validates Higher Rates of Metastatic Disease for European Association of Urology Biochemical Recurrence Risk Groups: An International Multicenter Study
por: Ferdinandus, Justin, et al.
Publicado: (2022)

Comprehensive adipocytic and neurogenic tissue microarray analysis of NY-ESO-1 expression - a promising immunotherapy target in malignant peripheral nerve sheath tumor and liposarcoma
por: Shurell, Elizabeth, et al.
Publicado: (2016)

The Friedman-Eilber Resection Arthroplasty of the Pelvis
por: Schwartz, Adam J., et al.
Publicado: (2009)

Cemented Endoprosthetic Reconstruction of the Proximal Tibia: How Long Do They Last?
por: Schwartz, Adam J., et al.
Publicado: (2010)

Cemented Distal Femoral Endoprostheses for Musculoskeletal Tumor: Improved Survival of Modular versus Custom Implants
por: Schwartz, Adam J., et al.
Publicado: (2009)

Evaluation of SUV normalized by lean body mass (SUL) in (68)Ga-PSMA11 PET/CT: a bi-centric analysis
por: Gafita, Andrei, et al.
Publicado: (2019)

The Potential of PET/MRI Imaging in Oncology: a Comment to a Summary Report of the First PET/MRI Workshop in Tuebingen in 2012
por: Czernin, Johannes, et al.
Publicado: (2013)

Correlation of (68)Ga-FAPi-46 PET Biodistribution with FAP Expression by Immunohistochemistry in Patients with Solid Cancers: Interim Analysis of a Prospective Translational Exploratory Study
por: Mona, Christine E., et al.
Publicado: (2022)

Tandem Isotope Therapy with (225)Ac- and (177)Lu-PSMA-617 in a Murine Model of Prostate Cancer
por: Meyer, Catherine, et al.
Publicado: (2023)

Phase 3 multicenter randomized trial of PSMA PET/CT prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer [PSMA dRT]: study protocol
por: Calais, Jeremie, et al.
Publicado: (2021)

Characterizing the immune microenvironment of malignant peripheral nerve sheath tumor by PD-L1 expression and presence of CD8+ tumor infiltrating lymphocytes
por: Shurell, Elizabeth, et al.
Publicado: (2016)

Gender dimorphism and age of onset in malignant peripheral nerve sheath tumor preclinical models and human patients
por: Shurell, Elizabeth, et al.
Publicado: (2014)

A Comprehensive Assessment of (68)Ga-PSMA-11 PET in Biochemically Recurrent Prostate Cancer: Results from a Prospective Multicenter Study on 2,005 Patients
por: Abghari-Gerst, Monica, et al.
Publicado: (2022)

Phase II Trial of Gemcitabine and Docetaxel with Bevacizumab in Soft Tissue Sarcoma
por: Dickson, Mark A., et al.
Publicado: (2015)

FDG PET/CT in Initial Staging of Adult Soft-Tissue Sarcoma
por: Roberge, David, et al.
Publicado: (2012)

Evaluating Thresholds to Adopt Hypofractionated Preoperative Radiotherapy as Standard of Care in Sarcoma
por: Valle, Luca F., et al.
Publicado: (2021)

Exposure–response relationship of olaratumab for survival outcomes and safety when combined with doxorubicin in patients with soft tissue sarcoma
por: Jones, Robin L., et al.
Publicado: (2018)

Effects of novel androgen receptor signaling inhibitors on PSMA PET signal intensity in patients with castrate-resistant prostate cancer: a prospective exploratory serial imaging study
por: Sonni, Ida, et al.
Publicado: (2023)

Studies of an alveolar soft tissue sarcoma.
por: Udekwu, F. A., et al.
Publicado: (1965)

High efficacy of tumor-targeting Salmonella typhimurium A1-R on a doxorubicin- and dactolisib-resistant follicular dendritic-cell sarcoma in a patient-derived orthotopic xenograft PDOX nude mouse model
por: Kiyuna, Tasuku, et al.
Publicado: (2016)

PET/CT in Oncology: Current Status and Perspectives
por: Czernin, Johannes, et al.
Publicado: (2013)

Delays in Referral of Soft Tissue Sarcomas
por: Johnson, G. D., et al.
Publicado: (2008)

Hibernoma in the Thigh Mimicking Soft Tissue Sarcoma on FDG-PET
por: Wimmer, Matthias, et al.
Publicado: (2015)

Soft-tissue Sarcomas
por: Vodanovich, Domagoj Ante, et al.
Publicado: (2018)

Prognostic factors for survival in soft tissue sarcoma.
por: el-Jabbour, J. N., et al.
Publicado: (1990)

Evaluation of In Vitro Activity of the Class I PI3K Inhibitor Buparlisib (BKM120) in Pediatric Bone and Soft Tissue Sarcomas
por: Anderson, Jennifer L., et al.
Publicado: (2015)

The role of radiology in paediatric soft tissue sarcomas
por: Park, K., et al.
Publicado: (2008)

PB1858: PROGNOSIS AND TREATMENT OF FLT3 MUTATED MYELOID SARCOMA IN THE ERA OF FLT3 INHIBITORS: RETROSPECTIVE EVALUATION IN 5 ITALIAN CENTERS.
por: Lessi, Federica, et al.
Publicado: (2023)

False positive PSMA PET for tumor remnants in the irradiated prostate and other interpretation pitfalls in a prospective multi-center trial
por: Fendler, Wolfgang P., et al.
Publicado: (2020)

Sarcoma Immunotherapy: Past Approaches and Future Directions
por: D'Angelo, S. P., et al.
Publicado: (2014)

Targeted therapies for the treatment of soft tissue sarcoma
por: Fuchs, Jeffrey W., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_582ak1dkmfk862sjtu40bu48sa